Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact

BACKGROUND: Meningococcal disease remains an important cause of morbidity and mortality worldwide. The first broadly effective vaccine against group B disease (which causes considerable meningococcal disease in Europe, the Americas and Australasia) was licensed in the EU in January 2013; our objecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Christensen, Hannah, Hickman, Matthew, Edmunds, W. John, Trotter, Caroline L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743045/
https://www.ncbi.nlm.nih.gov/pubmed/23566946
http://dx.doi.org/10.1016/j.vaccine.2013.03.034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743045/
https://www.ncbi.nlm.nih.gov/pubmed/23566946
http://dx.doi.org/10.1016/j.vaccine.2013.03.034

Ejemplares similares